How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

747 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease. Full Text available with Trip Pro

Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease. Disruption of cholinergic and serotonergic neurotransmitter systems is associated with cognitive, emotional and behavioural symptoms of Alzheimer's disease (AD). To investigate the responsiveness of these systems in AD we measured the effects of a single-dose of the selective serotonin reuptake inhibitor citalopram and acetylcholinesterase inhibitor galantamine in 12 patients with AD (...) coming from cerebrospinal fluid and white matter as covariates at the subject level, and baseline and heart rate measurements as confound regressors in the higher-level analysis (at p < 0.05, corrected). A galantamine induced difference between groups was observed for the cerebellar network. Connectivity within the cerebellar network and between this network and the thalamus decreased after galantamine vs. placebo in AD patients, but not in controls. For citalopram, voxelwise network connectivity did

2019 NeuroImage Controlled trial quality: uncertain

162. Pharmacological Management of Dementia with Lewy Bodies. Full Text available with Trip Pro

shown to be effective in managing the cognitive and behavioral symptoms of DLB: rivastigmine, galantamine and donepezil. Memantine is able to improve clinical global impression of change in those with mild to moderate DLB. Levodopa can treat the parkinsonism of some DLB patients, but the dose is often limited due to the fact that it can cause agitation or worsening of visual hallucinations. A recent phase 2 clinical trial showed the benefit of zonisamide when it is added as an adjunct to levodopa

2019 Drugs & Aging

163. Leaf extracts from Dendropanax morbifera Léveille mitigate mercury-induced reduction of spatial memory, as well as cell proliferation, and neuroblast differentiation in rat dentate gyrus. Full Text available with Trip Pro

and differentiated neuroblasts.Dimethylmercury (5 μg/kg) and galantamine (5 mg/kg) was administered intraperitoneally and/or DML (100 mg/kg) was orally to 7-week-old rats every day for 36 days. One hour after the treatment, novel object recognition test was examined. In addition, spatial probe tests were conducted on the 6th day after 5 days of continuous training in the Morris swim maze. Thereafter, the rats were euthanized for immunohistochemical staining analysis with Ki67 and doublecortin and measurement (...) the administration of DML or galantamine significantly increased the number of crossings than did dimethylmercury treatment alone. Proliferating cells and differentiated neuroblasts, assessed by Ki67 and doublecortin immunohistochemical staining was significantly decreased in the dimethylmercury treated group versus controls. Supplementation with DML or galantamine significantly increased the number of proliferating cells and differentiated neuroblasts in the dentate gyrus. In addition, treatment

2019 BMC Complementary and Alternative Medicine

164. Balaxur (memantine hydrochloride / donepezil hydrochloride)

, noradrenergic, and glutamatergic neurons. The incidence of Alzheimer's disease is approximately 10% in the population over 65 years of age and increases progressively with age to reach about 30% by the end of a century of life. Currently, available pharmacological therapies are the AChEI (e.g donepezil, galantamine and rivastigmine) and memantine that are acting on AD with different mechanisms of action (MoA) as explained above. Balaxur is a fixed-dose combination (FDC) product of memantine (20 mg

2013 European Medicines Agency - EPARs

166. Acrescent (memantine hydrochloride / donepezil hydrochloride)

donepezil, galantamine and rivastigmine) and memantine that are acting on AD with different mechanisms of action (MoA) as explained above. Acrescent is a fixed-dose combination (FDC) product of memantine (20 mg) and donepezil (10 mg), presented as film-coated tablets (memantine 20 mg/donepezil 10 mg). Acrescent has been developed as a substitution indication i.e. in patients adequately controlled with the individual products given concurrently at the same dose level as in the combination

2013 European Medicines Agency - EPARs

167. Generalized anxiety disorder

(such as haloperidol), antihistamines (such as mizolastine), and antiretrovirals (such as ritonavir, saquinavir, and lopinavir). Paroxetine: Avoid concurrent use with tamoxifen. Paroxetine is a potent inhibitor of the liver enzyme CYP2D6 and may reduce the plasma concentration of tamoxifen, leading to reduced efficacy. Paroxetine may increase the plasma concentrations of aripiprazole, clozapine, darifenacin, galantamine, methadone, metoprolol, pitolisant, procyclidine, ranolazine, risperidone and vortioxetine

2017 NICE Clinical Knowledge Summaries

168. Therapeutic interventions for aphasia initiated more than six months post stroke: a review of the evidence Full Text available with Trip Pro

, donepezil, memantine and galantamine were found to be effective in one RCT each. However, two RCTs demonstrated that bromocriptine was not effective. Three RCTs assessed brain stimulation techniques and found that both repetitive transcranial magnetic stimulation (rTMS) and anodal transcranial direct current stimulation (tDCS) improved naming abilities and lexical production. Two RCTs demonstrated that constraint-induced aphasia therapy was effective. Authors' conclusions There was evidence to support

2012 DARE.

169. Memantine in Combination with Cholinesterase Inhibitors for Alzheimer?s Disease: Clinical Effectiveness and Safety

://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823571 PubMed: PM19204022 Memantine in Combination with Cholinesterase Inhibitors for Alzheimer’s Disease 5 PREPARED BY: Canadian Agency for Drugs and Technologies in Health Tel: 1-866-898-8439 www.cadth.ca Memantine in Combination with Cholinesterase Inhibitors for Alzheimer’s Disease 6 APPENDIX – FURTHER INFORMATION: Guidelines and Consensus Statements 8. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease: review of NICE technology

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

170. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands Full Text available with Trip Pro

, in the Netherlands. CRD commentary Interventions: Memantine was appropriately compared with no pharmacological treatment. The authors stated that galantamine was another medical treatment for Alzheimer’s disease, but was not directly comparable. Effectiveness/benefits: The clinical data appear to have been from appropriate sources. The treatment effect was from a pooled analysis of clinical trials which should have ensured high internal validity. Other data were adjusted for the Netherlands, using a large local

2012 NHS Economic Evaluation Database.

171. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease

valid, but the clinical evidence was weak. Further studies are needed to support the authors’ findings. Type of economic evaluation Cost-utility analysis Study objective This study assessed the cost-effectiveness of adding memantine to the usual cholinesterase inhibitor treatment for patients with Alzheimer's disease. Interventions A cholinesterase inhibitor, donepezil, rivastigmine, or galantamine, was compared against memantine plus a cholinesterase inhibitor. Location/setting Canada/community

2012 NHS Economic Evaluation Database.

172. An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds. (Abstract)

, we demonstrate reversal of mecamylamine-induced neurophysiological effects due to 16 mg of galantamine as well as administering 21 mg of nicotine transdermally.Our findings indicate that the mecamylamine challenge model jointly with the nAChR index-a measure of the nicotinic EEG profile-could aid future proof-of-pharmacology studies to demonstrate effects of nicotinic cholinergic compounds.This novel measure for quantifying nicotinic cholinergic effects on the EEG could serve as a useful tool

2018 Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology Controlled trial quality: uncertain

173. Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses. Full Text available with Trip Pro

of the nicotinic antagonist mecamylamine on a battery of cognitive and neurophysiological test with coadministration of a placebo, nicotine or galantamine in order to reverse the cognitive impairment caused by mecamylamine.Thirty-three healthy subjects received a single oral dose of 30 mg of mecamylamine (or placebo) in combination with either 16 mg of oral galantamine or 21 mg of transdermal nicotine (or its double-dummy). Mecamylamine 30 mg induced significant disturbances of cognitive functions. Attention (...) and produced decrease in performance of tests evaluating motor coordination, sustained attention and short- and long-term memory. These effects could be partially reversed by the coadministration of nicotine, and to a lesser extent by galantamine.© 2018 The British Pharmacological Society.

2018 British journal of clinical pharmacology Controlled trial quality: uncertain

174. Serotonergic and cholinergic modulation of functional brain connectivity: A comparison between young and older adults. Full Text available with Trip Pro

) and the acetylcholinesterase inhibitor galantamine (8 mg) was measured in 12 young and 17 older volunteers during a randomized, double blind, placebo-controlled, crossover study. A powerful dataset consisting of 522 RS-fMRI scans was obtained by acquiring multiple scans per subject before and after drug administration. Group × treatment interaction effects on voxelwise connectivity with ten functional networks were investigated (p < .05, FWE-corrected) using a non-parametric multivariate analysis technique (...) with cerebrospinal fluid, white matter, heart rate and baseline measurements as covariates. Both groups showed a decrease in sensorimotor network connectivity after citalopram administration. The comparable findings after citalopram intake are possibly due to relatively similar serotonergic systems in the young and older subjects. Galantamine altered connectivity between the occipital visual network and regions that are implicated in learning and memory in the young subjects. The lack of a cholinergic response

2018 NeuroImage Controlled trial quality: uncertain

175. Touchscreen Technology and Art for People With Dementia in Care Homes

, Icchp 2016, Pt I, 9758, 509-514. doi:10.1007/978-3-319-41264-1_69 Mihailidis, A., Blunsden, S., Boger, J., Richards, B., Zutis, K., Young, L., & Hoey, J. (2010). Towards the development of a technology for art therapy and dementia: Definition of needs and design constraints. The Arts in Psychotherapy, 37(4), 293-300. NICE. (2011). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Retrieved from https://www.nice.org.uk/guidance/ta217 Smith, S. K. (2015

2018 Clinical Trials

176. ANAVEX2-73 Study in Parkinson's Disease Dementia

, dopamine agonists, MAO-B inhibitors, or the COMT inhibitor entacapone), which has been stable for at least 4 weeks prior to Baseline. Treatment with cholinesterase inhibitor (rivastigmine, donepezil and galantamine (Exelon®, Aricept®, or Reminyl®) will be permitted, provided the dose has been stable for a minimum of 8 weeks prior to randomization. Subjects with history of depression on antidepressant medications will be allowed if depression is controlled and they have been on a stable daily dose

2018 Clinical Trials

177. Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy Full Text available with Trip Pro

, among which galantamine is the only naturally occurring substance. However, several plant species producing diverse classes of alkaloids, coumarins, terpenes, and polyphenols have been assessed for their anti-AChE activity, becoming potential candidates for new anti-AD drugs. Therefore, this mini-review aimed to recapitulate last decade studies on the anti-AChE activity of plant species, their respective extracts, as well as isolated compounds. The anti-AChE activity of extracts prepared from 54

2018 Frontiers in pharmacology

178. Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review Full Text available with Trip Pro

Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review The increasing prevalence of Alzheimer's disease (AD) demands more effective drugs, which are still unclear. The aim of this study is to compare the effectiveness of six drugs, such as donepezil, rivastigmine, galantamine, memantine, huperzine-A, and tacrine, in senior AD patients and identify the most effective one to improve patients' cognitive function.A system of search strategies (...) the trials included.Among the 35 trials included, no obvious heterogeneity (I2=0.0%, P=0.583) was revealed according to the pooled data for cognition in NMA and the mean difference (MD) of memantine (MD=1.7, 95% CI: 0.73, 2.8) showed that the memantine was significantly efficacious in the treatment group in terms of MMSE. Followed by galantamine, huperzine-A, rivastigmine, tacrine, and donepezil.As the first NMA comparing the major drugs in market for AD, our study suggests that memantine might have

2018 Clinical interventions in aging

179. Strategies for Continued Successful Treatment in Patients with 
Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents Full Text available with Trip Pro

Strategies for Continued Successful Treatment in Patients with 
Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents Alzheimer's disease (AD) is the most common cause of dementia, characterized by a progressive decline in cognition and function. Current treatment options for AD include the cholinesterase inhibitors (ChEIs) donepezil, galantamine, and rivastigmine, as well as the N-methyl-Daspartate receptor antagonist memantine. Treatment guidelines recommend the use

2018 Current Alzheimer research

180. In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer's Disease Full Text available with Trip Pro

, and Salvadorin showed least binding energy and highest binding affinity among all the scrutinized compounds. Post-docking analyses showed the following free energy change for Albiziasaponin-A, Salvadorin, and Iso-Orientin (-9.8 to -15.0 kcal/mol) as compared to FDA approved drugs (donepezil, galantamine, and rivastigmine) for AD (-6.6 to -8.2 Kcal/mol) and interact with similar amino acid residues (Pro-266, Asp-344, Trp-563, Pro-568, Tyr-103, Tyr-155, Trp-317, and Tyr-372) with the target proteins

2018 Frontiers in pharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>